| Study | Drug | Trial design | Endpoint classification | Estimated enrollment | Outcomes | Status |
| NCT02481674 | VX15/2503 | Multicenter, randomized, double blind, placebo controlled, phase 2 trial. | Safety/efficacy | 84 | No published results. | Currently recruiting. Estimated primary completion date: August 2018. |
| NCT02215616 | Laquinimod | Multicenter, randomized, double blind, placebo controlled, phase 2 trial. | Safety/efficacy | 400 | No published results. | Currently recruiting. Estimated primary completion date: August 2017. |
| NCT01502046 | Cannabinoids: delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) | Randomized, double blind, crossover, placebo controlled, phase 2 trial. | Safety | 25 | No published results. | Completed. |
| NCT00146211 | Ethyl-EPA (Miraxion™, phospholipase A2 inhibitor) | Multicenter, randomized, double blind, placebo controlled, phase 3 trial. | Efficacy | 300 | 1Ethyl-EPA was generally well tolerated. Ethyl-EPA was not beneficial in patients with Huntington's disease. At 6 months, the Total Motor Score 4 point change for patients receiving ethyl-EPA did not differ from that for those receiving placebo. No differences were found in measures of function, cognition, or global impression [61]. | Completed. |
| NCT01357681 | Epigallocatechin gallate (EGCG) | Multicenter, randomized, double blind, placebo controlled, phase 2 trial. | Efficacy | 54 | No published results. | Completed. |
| NCT00029874 | Minocycline | Randomized, double blind, placebo controlled, phase 1/phase 2 trial. | Safety/efficacy | 63 | No published results. | Completed. |
| NCT00277355 | Minocycline | Multicenter, randomized, double blind, placebo controlled, phase 2/phase 3 trial. | Safety/efficacy | 114 | 2Minocycline at 100 and 200 mg/day for 8 weeks was well tolerated. No adverse events occurred more often with minocycline use [52]. | Completed. |
|
|